华仁药业：关于全资子公司盐酸奈福泮原料药获得上市申请批准通知书的公告

Core Viewpoint - Huaren Pharmaceutical announced the approval of its subsidiary Anhui Hengxing Pharmaceutical's application for the chemical raw material "Nafamostat Mesilate" by the National Medical Products Administration [2] Group 1 - The approval notification for "Nafamostat Mesilate" marks a significant milestone for Huaren Pharmaceutical and its subsidiary [2] - This approval allows the company to expand its product offerings in the pharmaceutical market [2] - The development reflects the company's ongoing commitment to innovation and compliance with regulatory standards [2]